Skip to content

Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Influenza Treatment System With Machine Learning

Autonomous Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Influenza Treatment System With Machine Learning in Outpatient Settings

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06052527
Enrollment
27
Registered
2023-09-25
Start date
2023-06-16
Completion date
2023-10-01
Last updated
2023-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Influenza, Post-COVID-19 Syndrome

Brief summary

This is an open-tabled, one-arm observatory trial to assess the effectiveness and safety of the Autonomous Treatment System Based on Machine Learning in patients with Covid-19, Post-Acute Sequelae of SARS-CoV-2 infection and influenza.

Detailed description

This study has enrolled 27 patients diagnosed with Covid-19, Post-Acute Sequelae of SARS-CoV-2 infection, and influenza. Of these patients, 26 are outpatients, and 1 is hospitalized. After screening based on the inclusion and exclusion criteria, eligible patients will receive prescriptions recommended by the Autonomous Treatment System Based on Machine Learning in this observational trial. The objectives of this study are: 1. To compare the classifications made by our machine learning system with those by physicians to assess the model's reliability and accuracy; 2. To evaluate Covid-19-related hospitalizations or deaths from any cause through day 28; 3. To determine if the machine learning system's recommended prescription alleviates symptoms of Covid-19, Post-Acute Sequelae of SARS-CoV-2 infection, and influenza; 4. To monitor participants who tested positive for the Covid-19 for 28 days after initiating treatment, looking for potential rebound cases. Participants will use an online application to receive the recommended prescription results and will forward these results to a physician for verification. Patients are instructed to complete the online analysis every 3 days or whenever their symptoms change, whichever comes first. They are also asked to adhere to the prescribed medication regimen. Research physicians will conduct follow-ups with patients every 3 days via phone calls. The potential treatments patients may receive include any of the following Traditional Chinese Medicine formulas: LizCovidCure-1, LizCovidCure-2, LizCovidCure-3, LizCovidCure-4, and LizCovid-5.

Interventions

OTHERAutonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning

A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning

Sponsors

Sheng'ai Traditional Chinese Medicine Hospital
CollaboratorUNKNOWN
Lizora LLC
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Either male or female (14 years or older), and their COVID-19 vaccination status was not a factor for inclusion. * Subjects with any high-risk conditions * Subjects with positive sars-cov-2 rapid antigen results in 30 days * Subjects with post Covid-19 syndrome

Exclusion criteria

* pregnant individuals * subjects with known histories of allergic reactions to medical herbs commonly used in Traditional Chinese Medicine (TCMs)

Design outcomes

Primary

MeasureTime frameDescription
Classification Accuracy1 Daycompare the classifications made by our machine learning system with those by physicians, to assess the model's reliability

Secondary

MeasureTime frameDescription
Hospitalization Rate and Death28 Dayswe assess Covid-19-related hospitalization or death from any cause through day 28

Other

MeasureTime frameDescription
Symptom Alleviation28 DaysDays of symptom disappearance
Re-infection Cases28 daysNumber of cases with recurrence-infection after treatment

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026